Lastly a third classification that grouped TP53 mutations according to the exon position (exon 8 vs. non-exon 8 mutations) was proposed by Canale et al. [18], where a significant negative impact of exon 8 TP53 mutations on Disease Control Rate (DCR) and PFS in EGFR mt+ NSCLC was shown, however only for the EGFR exon 19 deletion positive cases. This evidence concerns the gene EGFR and non-small cell lung carcinoma.